HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA double-strand break repair capacity

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 263-269

  Purrucker, Jan C ^a   Fricke, Andreas ^a   Ong, Mei Fang ^a   Rübe, Christian ^a   Rübe, Claudia E ^a   Mahlknecht, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Chromosomal stability; DSB repair; HDAC; HDAC inhibitors; Radiosensitivity

Indexed keywords

BUTYRIC ACID; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; VALPROIC ACID; VORINOSTAT;

ARTICLE; CHILD; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; ENZYME INHIBITION; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION;

BENZAMIDES; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FIBROBLASTS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICROSCOPY, FLUORESCENCE; PYRIDINES; SIGNAL TRANSDUCTION; SODIUM OXYBATE; TIME FACTORS; VALPROIC ACID;

EID: 76049119711     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000632     Document Type: Article

References (30)

1. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
2. Mahlknecht U and Hoelzer D: Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 6: 623-644, 2000.
3. Sato T, Friend C and De Harven E: Ultrastructural changes in Friend erythroleukemia cells treated with dimethyl sulfoxide. Cancer Res 31: 1402-1417, 1971.
4. Villar-Garea A and Esteller M: Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112: 171-178, 2004.
5. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG and Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163, 2003.
6. Mehler M: Epigenetics and the nervous system. Ann Neurol 64: 602-617, 2008.
7. Choo QY, Ho PC and Lin HS: Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr Pharm Des 14: 803-820, 2008.
8. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
9. Mei S, Ho AD and Mahlknecht U: Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int J Oncol 25: 1509-1519, 2004.
10. Arundel CM and Leith JT: Effects of nucleoside analogs and sodium butyrate on recovery from potentially lethal X ray damage in human colon tumor cells. Int J Radiat Oncol Biol Phys 13: 593-601, 1987.
11. Munshi A, Kurland JF, Nishikawa T, et al: Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912-4922, 2005.
12. Zhang Y, Jung M and Dritschilo A: Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161: 667-674, 2004.
13. Bar-Sela G, Jacobs KM and Gius D: Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells. Cancer J 13: 65-69, 2007.
14. Camphausen K and Tofilon P: Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 25: 4051-4056, 2007.
15. Karagiannis T and El-Osta A: Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25: 3885-3893, 2006.
16. Banuelos CA, Banáth JP, MacPhail SH, Zhao J, Reitsema T and Olive PL: Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res 13: 6816-6826, 2007.
17. Rube CE, Dong X, Kuhne M, et al: DNA double-strand break rejoining in complex normal tissues. Int J Radiat Oncol Biol Phys 72: 1180-1187, 2008.
18. Stoilov L, Darroudi F, Meschini R, van der Schans G, Mullenders LH and Natarajan AT: Inhibition of repair of X-ray-induced DNA double-strand breaks in human lymphocytes exposed to sodium butyrate. Int J Radiat Biol 76: 1485-1491, 2000.
19. Brown SL, Kolozsvary A, Liu J, Ryu S and Kim JH: Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat Res 169: 474-478, 2008.
20. Entin-Meer M, Rephaeli A, Yang X, Nudelman A, Vandenberg SR and Haas-Kogan DA: Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther 4: 1952-1961, 2005.
21. Hall E and Giaccia AJ: Radiobiology for the radiologist. Lippincott Wilkins & Williams, Philadelphia, PA, 2006.
22. Mahlknecht U and Schönbein C: Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica 93: 443-446, 2008.
23. Rube CE, Grudzenski S, Kuhne M, et al: DNA double-strand break repair of blood lymphocytes and normal tissues analysed in a preclinical mouse model: implications for radiosensitivity testing. Clin Cancer Res 14: 6546-6555, 2008.
24. Marchion DC, Bicaku E, Daud AI, Sullivan DM and Munster PN: Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65: 3815-3822, 2005.
25. Chinnaiyan P, Cerna D, Burgan W, et al: Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14: 5410-5415, 2008.
26. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA and Yen TJ: Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 160: 1017-1027, 2003.
27. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L and Jaulin C: Histone deacetylase inhibitors and genomic instability. Cancer Lett 274: 169-176, 2009.
28. Defoort EN, Kim PM and Winn LM: Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol 69: 1304-1310, 2006.
29. Rosato RR, Almenara JA and Grant S: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res 63: 3637-3645, 2003.
30. Browner WS, Kahn AJ, Ziv E, et al: The genetics of human longevity. Am J Med 117: 851-860, 2004.